摘要
目的观察来得时联合拜唐平治疗初发Ⅱ型糖尿病的临床疗效,并作安全性评价。方法将符合初发Ⅱ型糖尿病纳入标准病例90例,按入院顺序随机分为治疗组45例与对照组45例,对照组予以诺和灵30R治疗,治疗组给予来得时联合拜唐平治疗,比较两组的疗效,以及两组治疗前后各项实验室指标的变化情况。结果治疗组总有效率明显优于对照组(P<0.05),且治疗组在降低空服血糖、餐后2小时血糖及糖化血红蛋白水平方面均明显优于对照组(P<0.05或P<0.01)。治疗组低血糖发生率明显低于对照组,差异有统计学意义(P<0.05)。结论来得时联合拜唐平治疗初发Ⅱ型糖尿病疗效确切,安全有效,低血糖发生率低,值得临床推广应用。
Objective To observe the efficacy of lantus and metformin hydrochloride and glibenclamide tablets on primary type 2 diabetes. Methods 90 cases were randomly divided into treatment group （45 cases） and the control group （45 cases）. The treatment group was treated with lantus and metformin hydroehloride and glibenclamide tablets and the control group with Novolin. The laboratory parameters before and after treatment were observed. Results The treat- ment group in the lower flight blood glucose 2-hour postprandial blood glucose and glycosylated hemoglobin levels signifi- cantly better than the control group （P^0.05 or P^0. 01 ）. The incidence of hypoglycemia in the Treatment group was significantly lower than that of the control group. The difference was statistically significant （P〈0.05）. Conclusion It is safe and effective to treat primary type 2 diabetes with lantus and metformin hydrochloride and glibenelamide tablets.
出处
《西部医学》
2013年第9期1382-1383,共2页
Medical Journal of West China
关键词
初发Ⅱ型糖尿病
来得时
拜唐平
Primary type 2 diabetes
Lantus Metformin hydrochloride and glibenelamide tablets
